Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies
Open Access
- 1 January 2014
- journal article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 3 (7) , e180
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Identification of common variants influencing risk of the tauopathy progressive supranuclear palsyNature Genetics, 2011
- Inhibition of brain tumor growth by intravenous poly(β- l -malic acid) nanobioconjugate with pH-dependent drug releaseProceedings of the National Academy of Sciences, 2010
- Genome-wide association study reveals genetic risk underlying Parkinson's diseaseNature Genetics, 2009
- Transmission and spreading of tauopathy in transgenic mouse brainNature Cell Biology, 2009
- SROOGLE: webserver for integrative, user-friendly visualization of splicing signalsNucleic Acids Research, 2009
- Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating MechanismsMolecular Therapy, 2009
- Tau isoform regulation is region‐ and cell‐specific in mouse brainJournal of Comparative Neurology, 2008
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001